Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 4

Sponsor

Cancer Type

Genitourinary 5Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 11Colorectal Neoplasms 6Prostatic Neoplasms 5Ovarian Neoplasms 5Endometrial Neoplasms 4Colorectal Neoplasms, Hereditary Nonpolyposis 4Brain Neoplasms 3Urogenital Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Unknown Primary 2Hereditary Breast and Ovarian Cancer Syndrome 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8 1Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Primary Ovarian Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pancreatic Ductal Adenocarcinoma 1Neurofibromatosis 1 1Neoplastic Syndromes, Hereditary 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lipodystrophy, Familial Partial 1Leukemia, Myeloid, Acute 1

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Genetic Testing × Clear all
NCT06632977 2026-05-08

PREDICT

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
474 enrolled
Genitourinary

Prostatic Neoplasms

NCT07377006 2026-02-18

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

M.D. Anderson Cancer Center

Phase NA Not yet recruiting
108 enrolled
Genitourinary

Prostatic Neoplasms

NCT04763980 2025-12-31

Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer

University of California, San Francisco

Phase NA Recruiting
72 enrolled
Genitourinary

Prostatic Neoplasms

NCT04447703 2025-12-02

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study

Thomas Jefferson University

Phase NA Completed
346 enrolled
Genitourinary

Prostatic Neoplasms

NCT04067960 2024-08-14

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

Mayo Clinic

Phase EARLY_PHASE1 Completed
197 enrolled
CNSGastrointestinalGenitourinaryGynecologic

Brain Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡